請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58280
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳青周 | |
dc.contributor.author | Yu-Chin Lin | en |
dc.contributor.author | 林育靖 | zh_TW |
dc.date.accessioned | 2021-06-16T08:10:09Z | - |
dc.date.available | 2014-10-15 | |
dc.date.copyright | 2014-10-15 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-04-03 | |
dc.identifier.citation | Ahmed SM, Cohen EE (2007). Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. Curr Cancer Drug Targets 7: 666-673.
Ahsan A, Hiniker SM, Ramanand SG, Nyati S, Hegde A, Helman A et al (2010). Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res 70: 2862-2869. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE (2002). Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94: 344-351. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH et al (2002). Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV (2011). Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2: 222-233. Applebaum KM, Furniss CS, Zeka A, Posner MR, Smith JF, Bryan J et al (2007). Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst 99: 1801-1810. Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW et al (2011a). Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin Cancer Res 17: 5755-5764. Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ et al (2011b). Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. Invest New Drugs. Authier F, Metioui M, Bell AW, Mort JS (1999). Negative regulation of epidermal growth factor signaling by selective proteolytic mechanisms in the endosome mediated by cathepsin B. J Biol Chem 274: 33723-33731. Azijli K, Weyhenmeyer B, Peters GJ, de Jong S, Kruyt FA (2013). Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ 20: 858-868. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL et al (2008). Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300: 2754-2764. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH et al (2004). Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350: 1945-1952. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR (2010). Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33: 1304-1308. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006). Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH (2003). A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 63: 1727-1730. Bromann PA, Korkaya H, Courtneidge SA (2004). The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 23: 7957-7968. Brooks HD, Glisson BS, Bekele BN, Ginsberg LE, El-Naggar A, Culotta KS et al (2010). Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. Brooks HD, Glisson BS, Bekele BN, Ginsberg LE, El-Naggar A, Culotta KS et al (2011a). Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117: 2112-2119. Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A et al (2011b). Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117: 2112-2119. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R et al (2004). Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53: 1052-1059. Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E et al (2008). A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol 295: C836-843. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S et al (1996). Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488-2492. Carling D, Mayer FV, Sanders MJ, Gamblin SJ (2011). AMP-activated protein kinase: nature's energy sensor. Nat Chem Biol 7: 512-518. Chou CW, Wu MS, Huang WC, Chen CC (2011). HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One 6: e18087. Chou TC, Talalay P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55. Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C et al (2007). Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest 117: 2205-2215. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, Nyati MK (2006). Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 66: 981-988. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D et al (2004). Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5: 489-500. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB et al (2004). Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350: 1937-1944. Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J et al (2012). Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget 3: 395-398. Cufi S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, Lopez IA et al (2013). Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget 4: 1484-1495. Dehm SM, Bonham K (2004). SRC gene expression in human cancer: the role of transcriptional activation. Biochem Cell Biol 82: 263-274. Del Barco S, Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J et al (2011). Metformin: multi-faceted protection against cancer. Oncotarget 2: 896-917. Dong Y, Zhang M, Liang B, Xie Z, Zhao Z, Asfa S et al (2010). Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation 121: 792-803. Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM (2011). HGF-independent potentiation of EGFR action by c-Met. Oncogene 30: 3625-3635. Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, Stabile LP (2009). Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res 15: 6529-6540. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X (2000). Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275: 223-228. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R et al (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107: 351-362. Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, Yarden Y et al (2001). Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J Biol Chem 276: 27677-27684. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305. Falls DL (2003). Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 284: 14-30. Feng FY, Varambally S, Tomlins SA, Chun PY, Lopez CA, Li X et al (2007). Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene 26: 3431-3439. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA (2003). EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11: 507-517. Ferreira LM, Hebrant A, Dumont JE (2012). Metabolic reprogramming of the tumor. Oncogene 31: 3999-4011. Forastiere A, Koch W, Trotti A, Sidransky D (2001). Head and neck cancer. N Engl J Med 345: 1890-1900. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W et al (2003). Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098. Gill RK, Yang SH, Meerzaman D, Mechanic LE, Bowman ED, Jeon HS et al (2011). Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene 30: 3784-3791. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L et al (2000). Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 709-720. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA et al (2010). Diabetes and cancer: a consensus report. Diabetes Care 33: 1674-1685. Grassian AR, Metallo CM, Coloff JL, Stephanopoulos G, Brugge JS (2011). Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev 25: 1716-1733. Guarino M (2010). Src signaling in cancer invasion. J Cell Physiol 223: 14-26. Hackel PO, Zwick E, Prenzel N, Ullrich A (1999). Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11: 184-189. Haddad RI, Shin DM (2008). Recent advances in head and neck cancer. N Engl J Med 359: 1143-1154. Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, Dikic I (2003). Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 5: 461-466. Haglund K, Dikic I (2012). The role of ubiquitylation in receptor endocytosis and endosomal sorting. J Cell Sci 125: 265-275. Hardie DG (2013). AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 62: 2164-2172. Haskell MD, Slack JK, Parsons JT, Parsons SJ (2001). c-Src tyrosine phosphorylation of epidermal growth factor receptor, P190 RhoGAP, and focal adhesion kinase regulates diverse cellular processes. Chem Rev 101: 2425-2440. Herbst RS, Langer CJ (2002). Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 29: 27-36. Hetz C, Chevet E, Harding HP (2013). Targeting the unfolded protein response in disease. Nat Rev Drug Discov 12: 703-719. Higa GM, Fell RG (2013). Sex Hormone Receptor Repertoire in Breast Cancer. Int J Breast Cancer 2013: 284036. Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A et al (2005). Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23: 8636-8645. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T et al (2010). Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 3: 1077-1083. Hynes NE, Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO et al (2010). Metformin: taking away the candy for cancer? Eur J Cancer 46: 2369-2380. Jansen M, Ten Klooster JP, Offerhaus GJ, Clevers H (2009). LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol Rev 89: 777-798. Johnson FM, Saigal B, Talpaz M, Donato NJ (2005). Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11: 6924-6932. Johnson FM, Saigal B, Tran H, Donato NJ (2007). Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res 13: 4233-4244. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT et al (2010). Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 28: 4609-4615. Jung AC, Briolat J, Millon R, de Reynies A, Rickman D, Thomas E et al (2010a). Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int J Cancer 126: 1882-1894. Jung JH, Lee JO, Kim JH, Lee SK, You GY, Park SH et al (2010b). Quercetin suppresses HeLa cell viability via AMPK-induced HSP70 and EGFR down-regulation. J Cell Physiol 223: 408-414. Karni R, Jove R, Levitzki A (1999). Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 18: 4654-4662. Kaufmann T, Tai L, Ekert PG, Huang DC, Norris F, Lindemann RK et al (2007). The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell 129: 423-433. Kaufmann T, Strasser A, Jost PJ (2012). Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ 19: 42-50. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT et al (2009). HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 15: 3740-3750. Kuznetsov JN, Leclerc GJ, Leclerc GM, Barredo JC (2011). AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia. Mol Cancer Ther 10: 437-447. Le Roy C, Wrana JL (2005). Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 6: 112-126. Lee Y, Kim EK (2013). AMP-activated protein kinase as a key molecular link between metabolism and clockwork. Exp Mol Med 45: e33. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011). The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9-22. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009). New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625. Lin YC, Shun CT, Wu MS, Chen CC (2006). A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin Cancer Res 12: 7165-7173. Lin YC, Wu MH, Wei TT, Chuang SH, Chen KF, Cheng AL et al (2012). Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells. Neoplasia 14: 463-475. Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC et al (2012). Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 32: 1627-1637. Liu Yang HS, Robin L. Davisson and Ling Qi (2013). Phenformin Activates Unfolded Protein Response in an AMP-Activated Protein Kinase (AMPK)-Dependent Manner. J Biol Chem Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH (2002). Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 156: 843-854. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. Marignac VM, Smith S, Toban N, Bazile M, Aloyz R (2013). Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming. Oncotarget. Marmor MD, Yarden Y (2004). Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 23: 2057-2070. Marsden VS, O'Connor L, O'Reilly LA, Silke J, Metcalf D, Ekert PG et al (2002). Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 419: 634-637. Martin-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Garcia M et al (2010a). Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. Ann Oncol 21: 187-189. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA (2010b). Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9: 1057-1064. McFate T, Mohyeldin A, Lu H, Thakar J, Henriques J, Halim ND et al (2008). Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 283: 22700-22708. Meusser B, Hirsch C, Jarosch E, Sommer T (2005). ERAD: the long road to destruction. Nat Cell Biol 7: 766-772. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957. Moro L, Dolce L, Cabodi S, Bergatto E, Boeri Erba E, Smeriglio M et al (2002). Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. J Biol Chem 277: 9405-9414. Muti P, Berrino F, Krogh V, Villarini A, Barba M, Strano S et al (2009). Metformin, diet and breast cancer: an avenue for chemoprevention. Cell Cycle 8: 2661. Nardo G, Favaro E, Curtarello M, Moserle L, Zulato E, Persano L et al (2011). Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization. Cancer Res 71: 4214-4225. Nemere I, Pietras RJ, Blackmore PF (2003). Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem 88: 438-445. Oakhill JS, Steel R, Chen ZP, Scott JW, Ling N, Tam S et al (2011). AMPK is a direct adenylate charge-regulated protein kinase. Science 332: 1433-1435. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000). The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167. Osborne CK, Schiff R (2011). Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62: 233-247. Peres J (2010). HPV-positive oropharyngeal cancer: data may justify new approach. J Natl Cancer Inst 102: 1456-1459. Perillo B, Sasso A, Abbondanza C, Palumbo G (2000). 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20: 2890-2901. Pignon JP, le Maitre A, Maillard E, Bourhis J (2009). Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92: 4-14. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K et al (2012). EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13: 33-42. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA et al (2007). TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357: 2552-2561. Polanska H, Raudenska M, Gumulec J, Sztalmachova M, Adam V, Kizek R et al (2014). Clinical significance of head and neck squamous cell cancer biomarkers. Oral Oncol 50: 168-177. Rao RV, Ellerby HM, Bredesen DE (2004). Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 11: 372-380. Roskoski R, Jr. (2005). Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 331: 1-14. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ (1996). Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78: 1284-1292. Ruderman NB, Carling D, Prentki M, Cacicedo JM (2013). AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 123: 2764-2772. Salama JK, Seiwert TY, Vokes EE (2007). Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol 25: 4118-4126. Sen B, Peng S, Saigal B, Williams MD, Johnson FM (2011). Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin Cancer Res 17: 514-524. Shackelford DB, Shaw RJ (2009). The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9: 563-575. Shatalova EG, Klein-Szanto AJ, Devarajan K, Cukierman E, Clapper ML (2011). Estrogen and cytochrome P450 1B1 contribute to both early- and late-stage head and neck carcinogenesis. Cancer Prev Res (Phila) 4: 107-115. Shaw RJ (2009). LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 196: 65-80. Sikka A, Kaur M, Agarwal C, Deep G, Agarwal R (2012). Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle 11: 1374-1382. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792. Smeets SJ, Braakhuis BJ, Abbas S, Snijders PJ, Ylstra B, van de Wiel MA et al (2006). Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25: 2558-2564. Song G, Chen GG, Hu T, Lai PB (2010). Bid stands at the crossroad of stress-response pathways. Curr Cancer Drug Targets 10: 584-592. Sorkin A, Goh LK (2009). Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315: 683-696. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM (2005). Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65: 1459-1470. Summy JM, Gallick GE (2003). Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22: 337-358. Summy JM, Gallick GE (2006). Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 12: 1398-1401. Svotelis A, Bianco S, Madore J, Huppe G, Nordell-Markovits A, Mes-Masson AM et al (2011). H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERalpha ligand dependency. EMBO J 30: 3947-3961. Szegezdi E, Logue SE, Gorman AM, Samali A (2006). Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 7: 880-885. Talamonti MS, Roh MS, Curley SA, Gallick GE (1993). Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91: 53-60. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al (2006). Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531-2541. Terai K, Hiramoto Y, Masaki M, Sugiyama S, Kuroda T, Hori M et al (2005). AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol Cell Biol 25: 9554-9575. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM (2000). Recognition of the polyubiquitin proteolytic signal. EMBO J 19: 94-102. Ueo H, Matsuoka H, Sugimachi K, Kuwano H, Mori M, Akiyoshi T (1990). Inhibitory effects of estrogen on the growth of a human esophageal carcinoma cell line. Cancer Res 50: 7212-7215. Vakana E, Platanias LC (2011). AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget 2: 1322-1328. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417. Vandewynckel YP, Laukens D, Geerts A, Bogaerts E, Paridaens A, Verhelst X et al (2013). The paradox of the unfolded protein response in cancer. Anticancer Res 33: 4683-4694. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al (2008). Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009). Diabetes and cancer. Endocr Relat Cancer 16: 1103-1123. Vitale-Cross L, Molinolo AA, Martin D, Younis RH, Maruyama T, Patel V et al (2012). Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res (Phila) 5: 562-573. Wang G, Yang ZQ, Zhang K (2010). Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. Am J Transl Res 2: 65-74. Wang K, Lin B (2013). Inhibitor of apoptosis proteins (IAPs) as regulatory factors of hepatic apoptosis. Cell Signal 25: 1970-1980. Wang W, Dong L, Saville B, Safe S (1999). Transcriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol Endocrinol 13: 1373-1387. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ et al (2008). Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13: 385-393. Westra WH, Taube JM, Poeta ML, Begum S, Sidransky D, Koch WM (2008). Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 14: 366-369. Wheeler DL, Iida M, Dunn EF (2009). The role of Src in solid tumors. Oncologist 14: 667-678. Wilson KJ, Mill C, Lambert S, Buchman J, Wilson TR, Hernandez-Gordillo V et al (2012). EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors 30: 107-116. Wright JD, Reuter CW, Weber MJ (1996). Identification of sites on epidermal growth factor receptors which are phosphorylated by pp60src in vitro. Biochim Biophys Acta 1312: 85-93. Xi H, Barredo JC, Merchan JR, Lampidis TJ (2013). Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKbeta leading to autophagy. Biochem Pharmacol 85: 1463-1477. Xiao B, Sanders MJ, Underwood E, Heath R, Mayer FV, Carmena D et al (2011). Structure of mammalian AMPK and its regulation by ADP. Nature 472: 230-233. Yaghmaie F, Saeed O, Garan SA, Freitag W, Timiras PS, Sternberg H (2005). Caloric restriction reduces cell loss and maintains estrogen receptor-alpha immunoreactivity in the pre-optic hypothalamus of female B6D2F1 mice. Neuro Endocrinol Lett 26: 197-203. Yang PM, Liu YL, Lin YC, Shun CT, Wu MS, Chen CC (2010). Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res 70: 7699-7709. Yeatman TJ (2004). A renaissance for SRC. Nat Rev Cancer 4: 470-480. Youle RJ, Strasser A (2008). The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59. Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DM (2009a). Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326: 1707-1711. Zeqiraj E, Filippi BM, Goldie S, Navratilova I, Boudeau J, Deak M et al (2009b). ATP and MO25alpha regulate the conformational state of the STRADalpha pseudokinase and activation of the LKB1 tumour suppressor. PLoS Biol 7: e1000126. Zhou W, Slingerland JM (2014). Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat Rev Cancer 14: 26-38. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58280 | - |
dc.description.abstract | 本論文探討dasatinib引發頭頸癌細胞凋亡的藥理機轉。頭頸部鱗狀細胞癌(簡稱頭頸癌)是一個病程快速且預後不佳的世界性疾病。表皮生長因子受體(EGFR)會促進頭頸癌細胞的生長分裂,而其大量表現與頭頸癌的臨床預後不佳有關。雌激素受體(estrogen receptor)是一個作用廣泛的細胞核受體,能直接引發基因表現或是非基因表現的訊息傳遞。在頭頸癌中,雌激素受體會與表皮生長因子受體產生協同作用以促進細胞的生長與侵犯能力。近年來是標靶治療的時代,表皮生長因子受體的單株抗體cetuximab在頭頸癌成功的展現療效;儘管如此,cetuximab的效果仍然有限,頭頸癌整體治療成績仍然不佳,因此開發新的治療是重要課題。Dasatinib是一個對於Bcr-abl及Src均有抑制能力的磷酸激酶抑制劑(kinase inhibitor),已被核准用於慢性骨髓性白血病的臨床治療,也被認為對於固態腫瘤具有治療潛力。然而在dasatinib於頭頸癌的臨床試驗中,雖然僅有少數病人得到效果,然而Src的抑制與療效之間並無關連,推測應有Src以外的機轉決定dasatinib的療效。本研究的第一部分指出,表皮生長因子的分解是一個決定dasatinib是否引發頭頸癌細胞凋亡的關鍵步驟,而此步驟是經由溶小體(lysosome)所完成。此外,雌激素受體也參與表皮生長因子受體調控dasatinib引發的細胞凋亡。進一步在動物模式中証實,dasatinib的確會藉由負調控(down-regulation)表皮生長因子及雌激素受體而抑制頭頸癌的生長。
本研究的第二部分則是進一步發現,dasatinib引發之表皮生長因子分解是來自於AMPK引發的內質網壓力(ER stress)。Dasatinib會引發內質網壓力,再經由c-cbl的作用促進表皮生長因子受體之分解。Dasatinib所誘發的AMPK活化可能是來自於PDK4增加導致細胞內之ATP下降。metformin引發AMPK活化則會增強dasatinib在細胞模式及動物模式中抑制頭頸癌的效果,在人類頭頸癌的檢體也發現AMPK活化與表皮生長因子受體表現的相關性。本研究指出dasatinib是經由AMPK-dependent ER stress導致表皮生長因子受體分解及頭頸癌細胞凋亡,藉由活化AMPK會進一步加強dasatinib對頭頸癌的療效,為頭頸癌的治療帶來進步。 | zh_TW |
dc.description.abstract | The mechanism of dasatinib-induced apoptosis of head and neck squamous cell carcinoma (HNSCC) cells was investigated in this study. HNSCC is a worldwide disease with aggressive course and dismal outcome. The expression of epidermal growth factor receptor (EGFR) promotes cell growth and proliferation and is associated with clinical poor outcome of HNSCC. Estrogen receptor is a nuclear receptor which can exert both genomic and non-genomic actions. In HNSCC, estrogen receptor signaling is found to work in concert with EGFR to enhance cell growth and invasion. In the era of molecular targeted therapy, the emergence of cetuximab, an monoclonal antibody against EGFR, has led to a progress in HNSCC, but the efficacy is modest. Thus, new therapies are needed. Dasatinib is a Bcr-abl and Src inhibitor which has been approved for chronic myeloid leukemia and is expected to have activity against solid tumors. However, few patients benefit from dasatinib in clinical trials despite consistent Src inhibition, implicating that there are mechanisms beyond Src inhibition responsible for the efficacy of dasatinib. The first part of our study disclosed that EGFR degradation was the key event to mediate dasatinib-induced apoptosis in HNSCC cells. This event was through lysosome degradation. In addition, estrogen receptor was found to be associated with EGFR in dasatinib-induced apoptosis. Furthermore, xenograft model showed that dasatinib inhibited HNSCC tumor growth through in vivo down-regulation of EGFR and estrogen receptor.
In the second part of the study, we further investigated the mechanism of dasatinib-induced EGFR degradation and showed that AMPK-dependent endoplasmic reticulum (ER) stress is responsible for this event. Dasatinib induced ER stress which mediated EGFR degradation in a c-cbl-dependent manner. AMPK activation induced by dasatinib might be due to ATP decrease through the up-regulation of pyruvate dehydrogenase kinase 4 (PDK4). Furthermore, activation of AMPK by metformin sensitized dasatinib-induced in vitro and in vivo anti-cancer effect. The correlation of AMPK activation and EGFR expression was seen in HNSCC cells and human tumor specimens. Our results disclose that AMPK-dependent ER stress-mediated EGFR degradation plays a crucial role in the anti-cancer effect of dasatinib in HNSCC. Activation of AMPK by metformin might enhance dasatinib efficacy in HNSCC treatment. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T08:10:09Z (GMT). No. of bitstreams: 1 ntu-103-D98443007-1.pdf: 5630528 bytes, checksum: 4f7875894595fd336d9ada02892d0120 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | Abbreviation............................................2
中文摘要................................................4 Abstract in English.....................................5 Chapter I. Introduction 1. Head and neck squamous cell carcinoma (HNSCC)..6 2. Epidermal growth factor receptor (EGFR).......10 3. Src.......................................... 15 4. Estrogen receptor.............................19 5. BCL-2 family proteins and apoptosis...........22 6. Endoplasmic reticulum (ER) stress.............24 7. AMP-activated protein kinase (AMPK)...........26 8. Dasatinib and experimental rationale..........30 Chapter II. Materials and Methods......................31 Chapter III. Results Part I. Degradation of epidermal growth factor receptor (EGFR) mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.....................37 Part II. Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.......................57 Chapter IV. Conclusion and perspective.................75 Reference..............................................78 Publications and Honors................................94 | |
dc.language.iso | en | |
dc.title | Dasatinib在頭頸癌的藥理機轉研究 | zh_TW |
dc.title | The anti-cancer mechanism of dasatinib against head and neck squamous cell carcinoma (HNSCC) | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 張文昌,楊春茂,吳明賢,楊慕華,黃偉謙 | |
dc.subject.keyword | 標靶治療,頭頸癌,表皮生長因子受體,內質網壓力,腺?單磷酸活化蛋白激?, | zh_TW |
dc.subject.keyword | Dasatinib,HNSCC,EGFR,ER stress,AMPK, | en |
dc.relation.page | 95 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-04-07 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 5.5 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。